摘要
目的探讨CD28、CD117、趋化因子配体12(CXCL12)与多发性骨髓瘤患者髓外浸润的关系及对预后的评估价值,以期为临床早期制订干预方案提供参考。方法选取96例2020年5月至2022年5月在该院就诊的多发性骨髓瘤患者作为研究对象,根据是否发生髓外浸润分为发生组、未发生组,比较两组临床资料及CD28、CD117、CXCL12表达情况,分析CD28、CD117、CXCL12表达与多发性骨髓瘤患者髓外浸润的关系;随访6个月后,比较不同预后患者CD28、CD117、CXCL12表达情况,并分析其对多发性骨髓瘤预后的评估价值。结果本研究96例多发性骨髓瘤患者中发生髓外浸润38例(发生组),未发生58例(未发生组)。发生组CD28、CD117、CXCL12阳性患者比例高于未发生组(P<0.05);多因素Logistic回归分析结果显示,CD28、CD117、CXCL12阳性均为多发性骨髓瘤患者髓外浸润的独立危险因素(P<0.05)。随访6个月后,有21例多发性骨髓瘤患者死亡,且死亡患者入院时CD28、CD117、CXCL12阳性患者比例高于生存患者(P<0.05);多发性骨髓瘤CD28、CD117、CXCL12阳性患者的死亡风险分别为阴性患者的7.091、29.231、20.143倍(P<0.05)。结论CD28、CD117、CXCL12阳性可用于评估多发性骨髓瘤患者髓外浸润情况,为临床早期预测预后提供参考,以针对性地展开后续治疗,改善预后。
Objective To investigate the relationship between CD28,CD117,chemokine ligand 12(CXCL12)and extramedullary infiltration in patients with multiple myeloma and the assessment value of prognosis,so as to provide reference for early clinical intervention.Methods Ninety-six patients with multiple myeloma who attended the hospital from May 2020 to May 2022 were selected as the study subjects,which were divided into the occurrence group and the non-occurrence group according to whether or not the extramedullary infiltration occurred,and the clinical data and expressions of CD28,CD117 and CXCL12 in the two groups were compared,the relationship between the expression of CD28,CD117,and CXCL12 and extramedullary infiltration in patients with multiple myeloma were analyzed.After 6-month follow-up,the expressions of CD28,CD117 and CXCL12 in patients with different prognosis were compared,and their evaluation value of CD28,CD117 and CXCL12 for the prognosis of multiple myeloma were analyzed.Results Among 96 patients with multiple myeloma,extramedullary infiltration occurred in 38 cases(occurrence group)and the rest 58 cases were non-occurrence group.The proportions of patients with positive CD28,CD117 and CXCL12 in the occurrence group were higher than those in the non-occurrence group(P<0.05),and multivariate Logistic regression analysis showed that the positive expressions of CD28,CD117 and CXCL12 were all independent risk factors for extramedullary infiltration in patients with multiple myeloma(P<0.05).After 6 months of follow-up,21 patients died,and the proportions of positive expressions of CD28,CD117 and CXCL12 in died patients were higher than those in survival patients(P<0.05).The risk of death in multiple myeloma patients with positive expressions of CD28,CD117 and CXCL12 was 7.091,29.231 and 20.143 times higher than that in multiple myeloma patients with negative expressions of CD28,CD117 and CXCL12,respectively(P<0.05).Conclusion Positive expressions of CD28,CD117 and CXCL12 can be used to evaluate extramedullary in
作者
蔡永梅
CAI Yongmei(Department of Laboratory Medicine,Jiyuan People′s Hospital,Jiyuan,Henan 459000,China)
出处
《检验医学与临床》
CAS
2024年第9期1294-1297,1302,共5页
Laboratory Medicine and Clinic
